tas-303
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2015 (NCT02562807)
Timeline
Indications
Mechanism of action
- Norepinephrine transporterINHIBITOR
SC6A2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
[2H]C([2H])([2H])C([2H])([2H])C([2H])([2H])OC(C(=O)OC1CCNCC1)(c1ccccc1)c1ccccc1- Mol. weight
- 360.5 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095507 ↗
- ChEMBLCHEMBL5095197 ↗
Also known as
- tas-303
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05621447 | Phase 1 | Sep 7, 2022 | Otsuka |
| NCT04512053 | Phase 2 | Sep 30, 2020 | Otsuka |
| NCT02906683 | Phase 2 | Oct 1, 2016 | Otsuka |
| NCT02562807 | Phase 1 | Oct 1, 2015 | Otsuka |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Otsuka | For profit | 4 | 4 | 2 | 2015 |
1 organizations
Page 1 / 1